Innovating Works

ALMIRALL

Activa
Mostrando 1 al 20 de 21 resultados
FACILITATE: FrAmework for ClInicaL trIal participants daTA reutilization for a fully Transparent and Ethical eco... ALMIRALL participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage FACILITATE is a project built on a patient-centered, data-driven, technological platform where an innovative data sharing and re-use process...
2021-10-11 - 2025-12-31 | Financiado
PROPEL: PROPEL ENERGY EFFICIENCY FINANCE ALMIRALL participó en un H2020: H2020-LC-SC3-2018-2019-2020 The potential for mainstreaming energy efficiency financing will be addressed by the PROPEL consortium by creating a single, holistic resour...
2021-05-06 - 2023-11-30 | Financiado
BIOMAP: Biomarkers in Atopic Dermatitis and Psoriasis ALMIRALL participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage Our objective is to provide a taxonomic and predictive systems medicine model of Atopic Dermatitis and Psoriasis based on clinical and molec...
2019-02-27 - 2025-03-31 | Financiado
BioHealx: Anal Fistula Treatment ALMIRALL participó en un H2020: H2020-EIC-SMEInst-2018-2020 Signum Surgical Ltd. is a medical device company developing a solution to anal fistula disease. Anal fistulas are a common rectal disease af...
2019-02-20 - 2022-06-30 | Financiado
MULTI2HYCAT: MULTI site organic inorganic HYbrid CATalysts for MULTI step chemical processes ALMIRALL participó en un H2020: H2020-NMBP-2016-2017 The main goal of MULTI2HYCAT is to design, obtain proof of concept (2 gr.) and upscale in a pre-pilot reactor (20-50 gr.) a new class of hie...
2016-11-22 - 2021-06-30 | Financiado
IbD: Intensified by Design for the intensification of processes involving solids handling ALMIRALL participó en un H2020: H2020-SPIRE-2014-2015 IbD® will create a holistic platform for facilitating process intensification in processes in which solids are an intrinsic part, the corner...
2015-08-07 - 2018-08-31 | Financiado
OPEN PHACTS: The Open Pharmacological Concepts Triple Store ALMIRALL participó en un FP6: Drug discovery is data-hungry and all major pharmaceutical companies maintain extensive in-house instances of public data alongside internal...
2011-03-01 - 2016-02-29 | Financiado
SAFESCIMET: European Modular Education and Training Programme in Safety Sciences for Medicines ALMIRALL participó en un FP6: Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has...
2010-01-01 - 2016-09-30 | Financiado
EMTRAIN: European Medicines Research Training Network ALMIRALL participó en un FP6: EMTRAIN is an essential element for the success of the IMI Education & Training (E&T) Call Topics in Europe (current and future). It will es...
2009-10-01 - 2016-09-30 | Financiado
U-BIOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes ALMIRALL participó en un FP6: RationaleThe inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma this...
2009-10-01 - 2015-09-30 | Financiado
EU2P: European programme in Pharmacovigilance and Pharmacoepidemiology ALMIRALL participó en un FP6: The Eu2P training network in Pharmacovigilance and Pharmacoepidemiology will meet the needs of industry,regulatory authorities and academia...
2009-09-01 - 2016-06-30 | Financiado
PRO- ACTIVE: Physical Activity as a Crucial Patient Reported Outcome in COPD ALMIRALL participó en un FP6: Physical activity (PA) is essential in maintaining optimal health in chronic diseases, including COPD.More physically active patients have l...
2009-09-01 - 2016-05-31 | Financiado
SAFE-T: SAFER AND FASTER EVIDENCE-BASED TRANSLATION ALMIRALL participó en un FP6: The public-private consortium composed of complementary SMEs, academic and clinical centers of excellence and EMEA as partner proposes SAFE-...
2009-06-15 - 2015-06-14 | Financiado
OPEN PHACTS: The Open Pharmacological Concepts Triple Store ALMIRALL participó en un FP7: Drug discovery is data-hungry and all major pharmaceutical companies maintain extensive in-house instances of public data alongside internal...
Financiado
SAFESCIMET: European Modular Education and Training Programme in Safety Sciences for Medicines ALMIRALL participó en un FP7: Background: In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall ha...
Financiado
U-BIOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes ALMIRALL participó en un FP7: Rationale The inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma thi...
Financiado
PHARMATRAIN: Pharmaceutical Medicine Training Programme "The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug developm...
Financiado
PRO- ACTIVE: Physical Activity as a Crucial Patient Reported Outcome in COPD ALMIRALL participó en un FP7: Physical activity (PA) is essential in maintaining optimal health in chronic diseases, including COPD.More physically active patients have l...
Financiado
EMTRAIN: European Medicines Research Training Network ALMIRALL participó en un FP7: EMTRAIN is an essential element for the success of the IMI Education & Training (E&T) Call Topics in Europe (current and future). It will es...
Financiado
EU2P: European programme in Pharmacovigilance and Pharmacoepidemiology ALMIRALL participó en un FP7: The Eu2P training network in Pharmacovigilance and Pharmacoepidemiology will meet the needs of industry,regulatory authorities and academia...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.